Dr. Agastin Michael, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 171 Huguenot Street, New Rochelle, NY 10801 Phone: 914-607-5800 Fax: 914-607-5821 |
Dr. Ajay Verma, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 421 Huguenot Street, Suite 33, New Rochelle, NY 10801 Phone: 914-632-6060 Fax: 914-632-6218 |
Dr. Richard Saitta, M.D. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 140 Lockwood Ave, New Rochelle, NY 10801 Phone: 914-235-6878 |
Dr. Kameswari Desiraju Lakshmi, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 175 Memorial Hwy Ste Ll2, New Rochelle, NY 10801 Phone: 914-365-1616 Fax: 914-233-3514 |
News Archive
Reuters reports on the recent efforts by India's government to expand welfare programs throughout the country: "Since helping the Congress party win re-election last year, welfare has fast become the government's knee-jerk answer to policy dilemmas as it tries to ease food inflation, help growth trickle down to the poor, and win hearts and minds in" the country, the news service writes.
The Franklin Institute has received a $2.5 million contribution from leading global pharmaceutical company Teva Pharmaceuticals to develop a signature innovative exhibit at the museum exploring neuroscience and the human brain, entitled Your Brain. This contribution brings The Franklin Institute's Inspire Science fundraising campaign total to $65 million.
Valentines Party planned for the blind and the disabled on Tuesday, February 16, 2010. Event will be held at the Visually Handicapped Adults of the Valley (VHAV), 15520 Sherman Way, Van Nuys, CA 91406.
Mylan Inc. today announced it has completed the acquisition of Bioniche Pharma Holdings Limited sooner than anticipated.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.
› Verified 1 days ago